Proteomic Based Drug Discovery Summit 2025

Conference themes
Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.

This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.

Scientific Society
Hanson Wade

Notes
Brochure: https://go.evvnt.com/2674449-3?pid=4832

Speakers: Alex Campos, Senior Director - Systems Biology and Proteomics, Plexium Inc., Bekim Bajrami, Associate Scientific Director, Biogen and more.

https://go.evvnt.com/2674449-2?pid=4832

Ms. Lucy Rutherford